Treatment Patterns, Healthcare Utilization, and Related Costs for Prurigo Nodularis in Sweden
DOI:
https://doi.org/10.2340/actadv.v105.43730Keywords:
prurigo nodularis, epidemiology, costs, treatment patterns, healthcare resource utilizationAbstract
Prurigo nodularis (PN) is a chronic, itchy, inflammatory skin condition that negatively affects quality of life. A study was undertaken to investigate the healthcare utilization, including treatment patterns and direct costs for specialist care, for PN in Sweden. Linkage cohorts were created from national Swedish patient and prescription registers, and the cost-per-patient database of PN adults in specialist care in Sweden from 2015 to 2020. Around 875 patients were registered annually with a specialist diagnosis of PN in Sweden, with 3,548 specialist visits per year on average. In patients with severe PN with AD, the most common treatment sequence was topical treatment with corticosteroids followed by systemic prednisolone and methotrexate (32.6%). More than one-fifth of individuals with PN, and most with severe PN, had treatment for more than 1 year. For in- and outpatient care, the mean cost per visit was €458.6 and per patient per year around €1,862. The total annual cost of PN patients is estimated to be €1.6 million in Sweden. A high proportion of patients are treated for years with several, often systemic, treatment sequels. Targeted treatments for PN might improve patients’ quality of life and reduce the high related costs for the healthcare system.
Downloads
References
Huang AH, Williams KA, Kwatra SG. Prurigo nodularis: epidemiology and clinical features. J Am Acad Dermatol 2020; 83: 1559–1565. DOI: https://doi.org/10.1016/j.jaad.2020.04.183
Kwatra SG. Breaking the itch–scratch cycle in prurigo nodularis. N Engl J Med 2020; 382: 757–758. DOI: https://doi.org/10.1056/NEJMe1916733
Leis M, Fleming P, Lynde CW. Prurigo nodularis: review and emerging treatments. Skin Therapy Lett 2021; 26: 5–8. PMID: 34077168.
Mollanazar NK, Sethi M, Rodriguez RV, Nattkemper LA, Ramsey FV, Zhao H, et al. Retrospective analysis of data from an itch center: integrating validated tools in the electronic health record. J Am Acad Dermatol 2016; 75: 842–844. DOI: https://doi.org/10.1016/j.jaad.2016.05.035
Huang AH, Canner JK, Khanna R, Kang S, Kwatra SG. Real-world prevalence of prurigo nodularis and burden of associated diseases. J Invest Dermatol 2020; 140: 480–483. DOI: https://doi.org/10.1016/j.jid.2019.07.697
Larson VA, Tang O, Ständer S, Miller LS, Kang S, Kwatra SG. Association between prurigo nodularis and malignancy in middle-aged adults. J Am Acad Dermatol 2019; 81: 1198–1201. DOI: https://doi.org/10.1016/j.jaad.2019.03.083
Whang KA, Le TK, Khanna R, Williams KA, Roh YS, Sutaria N, et al. Health-related quality of life and economic burden of prurigo nodularis. J Am Acad Dermatol 2022; 86: 537–580. DOI: https://doi.org/10.1016/j.jaad.2021.05.036
Antelmi A, Metsini A, Regnell SE, Carlberg M, Svensson Å, von Kobyletzki L. Prevalence of prurigo nodularis in Sweden. J Eur Acad Dermatol Venereol 2024; 38: 904–906. DOI: https://doi.org/10.1111/jdv.19986
Morgan CL, Thomas M, Ständer S, Jabbar-Lopez ZK, Piketty C, Gabriel S, et al. Epidemiology of prurigo nodularis in England: a retrospective database analysis. Br J Dermatol 2022; 187: 188–195. DOI: https://doi.org/10.1111/bjd.21032
Ständer S, Pereira MP, Berger T, Zeidler C, Augustin M, Bobko S, et al. IFSI-Guideline on chronic prurigo including prurigo nodularis. Itch 2020; 5: 1–13. DOI: https://doi.org/10.1097/itx.0000000000000042
Elmariah S, Kim B, Berger T, Chisolm S, Kwatra SG, Mollanazar N, et al. Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus. J Am Acad Dermatol 2021; 84: 747–760. DOI: https://doi.org/10.1016/j.jaad.2020.07.025
SKR-SALAR. Cost Per Patient database: Swedish Association of Local Authorities and Regions. Available from: https://skr.se/skr/halsasjukvard/ekonomiavgifter/kostnadperpatientkpp/kppdatabas.46722.html (last accessed 7 July 2023).
National Board of Health and Welfare – Socialstyrelsen. Classification of action codes (KVÅ). Available from: https://www.socialstyrelsen.se/statistik-och-data/klassifikationer-och-koder/kva/ (last accessed 7 July 2023).
Ryczek A, Reich A. Prevalence of prurigo nodularis in Poland. Acta Derm Venereol 2020; 100: adv00155. DOI: https://doi.org/10.2340/00015555-3518
Bahloul D, Hudson R, Balogh O, Mathias E, Heywood B, Hubbuck E, et al. Prevalence, incidence and treatment patterns of prurigo nodularis in England: a retrospective database analysis. Br J Dermatol 2024; 91: 548–555. DOI: https://doi.org/10.1093/bjd/ljae207
Boozalis E, Tang O, Patel S, Semenoc YR, Pereira MP, Ständer S, et al. Ethnic differences and comorbidities of 909 prurigo nodularis patients. J Am Acad Dermatol 2018; 79: 714–719. DOI: https://doi.org/10.1016/j.jaad.2018.04.047
Ständer S, Augustin M, Berger T, Elmariah S, Korman NJ, Weisshaar W, et al. Prevalence of prurigo nodularis in the United States of America: a retrospective database analysis. JAAD Int 2020; 2: 28–30. DOI: https://doi.org/10.1016/j.jdin.2020.10.009
Misery L, Brenaut E, Torreton E, Bonte J, Bouée S. Prevalence and management of chronic nodular prurigo (CNPG) in Brittany (France): estimation by matching two databases. J Eur Acad Dermatol Venereol 2021; 5: 602–604. DOI: https://doi.org/10.1111/jdv.17333
Bahloul D, Hudson R, Balogh O, Mathias E, Heywood B, Hubbuck E, et al. Estimating the healthcare burden of prurigo nodularis in England: a CPRD database study. J Dermatolog Treat 2024; 35: 2367615. DOI: https://doi.org/10.1080/09546634.2024.2367615
Whang KA, Kang S, Kwatra SG. Inpatient burden of prurigo nodularis in the United States. Medicines 2019; 6: 88. DOI: https://doi.org/10.3390/medicines6030088
Huang AH, Canner JK, Williams KA, Grossberg AL, Kwatra MM, Kwatra SG. Healthcare resource utilization and payer cost analysis of patients with prurigo nodularis. Br J Dermatol 2020; 183: 182–184. DOI: https://doi.org/10.1111/bjd.18925
Wongvibulsin S, Sutaria N, Williams KA, Huang AH, Choi J, Roh YS, et al. A nationwide study of prurigo nodularis: disease burden and healthcare utilization in the United States. J Invest Dermatol 2021; 141: 2530–2533. DOI: https://doi.org/10.1016/j.jid.2021.02.756
Ständer S, Ketz M, Akumo D, Kossack N, Pignot M, Chavda R, et al. Comorbidities, healthcare resource utilization & treatment pattern among patients with prurigo nodularis, compared to a benchmark in Germany: a real-world evidence claims data study. J Eur Acad Dermatol Venereol 2024; 38: 883–894. DOI: https://doi.org/10.1111/jdv.19700
Additional Files
Published
How to Cite
License
Copyright (c) 2025 Laura von Kobyletzki, Alexandra Metsini, Simon E. Regnell, Michael Carlberg, Åke Svensson, Annarita Antelmi
This work is licensed under a Creative Commons Attribution 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
